BIO-TECHNE CORP

Merck KGaA’s $11.3 B cash takeover of Bio‑Techne fuels a record U.S. life‑science deal, boosting its diagnostics portfolio and market reach—what this means for investors and the industry.

Merck’s $11.3 billion cash bid for Bio‑Techne boosts its laboratory‑equipment dominance, offers a 24% premium to shareholders, and expands U.S. reach.

Bio‑Techne’s Q3 2026 earnings reveal a 2% revenue dip, modest EPS rise, and a cautious dividend, raising doubts over margin growth and long‑term biotech innovation.

Investors who bought Bio‑Techne shares five years ago saw a loss as prices slid from $79.39 to $58.81—see why the biotech stock’s high P/E and volatility mean careful risk assessment matters.

Bio‑Techne’s earnings beat fuels an after‑hours rally, showing that a robust proteins & cytokines pipeline and upgraded guidance can lift a high‑PE biotech stock toward investor focus.